Prediabetic State

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

5100%

+ 10 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

Dapagliflozin 10mgPhase 41 trial

DapagliflozinPhase 2Small Molecule

Active Trials

NCT03721874Completed16Est. Jun 2021

Medica CorpMA - Bedford

1 program

Vanadyl sulfatePhase 31 trial

Active Trials

NCT00561132Completed14Est. Nov 2004

SandozAustria - Kundl

1 program

vildagliptinPhase 3Small Molecule1 trial

Active Trials

NCT00237250Completed171Est. Jul 2006

BayerLEVERKUSEN, Germany

1 program

DapagliflozinPhase 2Small Molecule

Nordic PharmaFrance - Paris

1 program

DapagliflozinPhase 2Small Molecule1 trial

Active Trials

NCT02695810Completed120Est. Jan 2019

Colorado TherapeuticsCO - Louisville

2 programs

CookingMattersN/A1 trial

PresessionsN/A1 trial

Active Trials

NCT03527641Completed20Est. Apr 2019

NCT04022499Completed483Est. Aug 2024

LabcorpBURLINGTON, NC

1 program

Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetesN/A1 trial

Active Trials

NCT06195566Unknown75Est. Mar 2025

Human BioSciencesWV - Martinsburg

1 program

Financial IncentivesN/A1 trial

Active Trials

NCT02422420Completed1,500Est. Sep 2016

Shield TherapeuticsMA - Wellesley

1 program

JOOL Health Mobile Phone ApplicationN/A1 trial

Active Trials

NCT03025607Completed69Est. Mar 2018

Angeles TherapeuticsCA - Los Angeles

1 program

Shared decision-making with pharmacistsN/A1 trial

Active Trials

NCT02384109Completed521Est. Jun 2019

MSDIreland - Ballydine

1 program

Sitagliptin + Pioglitazone PLACEBON/A

Sharp TherapeuticsPA - Pittsburgh

1 program

Sitagliptin + Pioglitazone PLACEBON/A

NovartisBASEL, Switzerland

1 program

vildagliptinPHASE_3Small Molecule

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

AstraZenecaDapagliflozin 10mg

Sandozvildagliptin

Medica CorpVanadyl sulfate

Nordic PharmaDapagliflozin

LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Colorado TherapeuticsPresessions

Colorado TherapeuticsCookingMatters

Shield TherapeuticsJOOL Health Mobile Phone Application

Angeles TherapeuticsShared decision-making with pharmacists

Human BioSciencesFinancial Incentives

Clinical Trials (10)

Total enrollment: 2,989 patients across 10 trials

NCT03721874 AstraZenecaDapagliflozin 10mg

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation

Start: Apr 2019Est. completion: Jun 202116 patients

Phase 4Completed

NCT00237250 Sandozvildagliptin

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Start: Oct 2005Est. completion: Jul 2006171 patients

Phase 3Completed

NCT00561132 Medica CorpVanadyl sulfate

Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance

Start: Nov 2003Est. completion: Nov 200414 patients

Phase 3Completed

NCT02695810 Nordic PharmaDapagliflozin

The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

Start: Feb 2016Est. completion: Jan 2019120 patients

Phase 2Completed

NCT06195566 LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Start: Jan 2024Est. completion: Mar 202575 patients

N/AUnknown

NCT04022499 Colorado TherapeuticsPresessions

Presessions for the National Diabetes Prevention Program

Start: Aug 2019Est. completion: Aug 2024483 patients

N/ACompleted

NCT03527641 Colorado TherapeuticsCookingMatters

United for Health: Type 2 Diabetes Prevention in Latino Teens

Start: May 2018Est. completion: Apr 201920 patients

N/ACompleted

NCT03025607 Shield TherapeuticsJOOL Health Mobile Phone Application

A Mobile Phone-based Program for Adults With Prediabetes

Start: May 2017Est. completion: Mar 201869 patients

N/ACompleted

NCT02384109 Angeles TherapeuticsShared decision-making with pharmacists

A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program

Start: Jun 2015Est. completion: Jun 2019521 patients

N/ACompleted

NCT02422420 Human BioSciencesFinancial Incentives

Minnesota Medicaid Incentives to Prevent Chronic Disease

Start: Mar 2013Est. completion: Sep 20161,500 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.